0 155

Cited 9 times in

Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041)

 Jung-Yun Lee  ;  Jeong-Yeol Park  ;  Sang Yoon Park  ;  Jeong-Won Lee  ;  Jae Weon Kim  ;  Yong Beom Kim  ;  Dae Hoon Jeong  ;  Kwang-Beom Lee  ;  Tae-Hun Kim  ;  In Ho Lee  ;  Min Chul Choi  ;  Ki Hyung Kim  ;  Yong-Man Kim  ;  Yong Jae Lee  ;  Sokbom Kang  ;  KGOG Investigators  ;  Eric Pujade-Lauraine 
 GYNECOLOGIC ONCOLOGY, Vol.152(1) : 61-67, 2019 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Bevacizumab/administration & dosage ; Doxorubicin/administration & dosage ; Doxorubicin/analogs & derivatives ; Drug Resistance, Neoplasm ; Female ; Humans ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy* ; Neoplasm Recurrence, Local/mortality ; Ovarian Neoplasms/drug therapy* ; Ovarian Neoplasms/mortality ; Paclitaxel/administration & dosage ; Platinum/therapeutic use ; Polyethylene Glycols/administration & dosage ; Topotecan/administration & dosage
Bevacizumab ; Chemotherapy ; Ovarian cancer ; Platinum-resistant ; Real world
PURPOSE: To evaluate the effectiveness of bevacizumab with single-agent chemotherapy for platinum-resistant ovarian cancer in a real-world setting. PATIENTS AND METHODS: We enrolled recurrent platinum-resistant ovarian cancer patients from 27 institutions. All had received bevacizumab with single-agent chemotherapy (weekly paclitaxel, pegylated liposomal doxorubicin (PLD), topotecan) between 2015 and 2017 for second- or third-line chemotherapy in routine clinical practice. The primary endpoint was progression-free survival (PFS) and safety. Secondary endpoints included the objective response rate (ORR), PFS2, overall survival, duration of chemotherapy, and reasons for discontinuing chemotherapy. RESULTS: Of 391 patients, 259 (66.2%) received bevacizumab with PLD, 94 (24.0%) with topotecan, and 38 (9.7%) with weekly paclitaxel. The median PFS was 6.1 months with all forms of bevacizumab-containing therapy. Although the cohort with weekly paclitaxel had a better PFS than the PLD cohort (P = 0.028), this finding was not found in patients with a previous platinum-free interval of less than three months. The median duration of therapy was five cycles (range, one to 20 cycles), and 29 patients (7.4%) discontinued treatment because of adverse events from bevacizumab-containing regimens. The PLD cohort had fewer grade ≥ 3 adverse events than the other regimens (PLD, 35.8%; weekly paclitaxel, 52.6%; topotecan, 51.1%; P = 0.012), especially events of hematologic toxicities. CONCLUSION: In Korean ovarian cancer patients, the safety and effectiveness of chemotherapy with bevacizumab in a real-world setting was consistent with the results from a randomized controlled study. The effectiveness and toxicity profiles varied among the chemotherapy regimens, and this finding should be considered in practice. CLINICAL TRIALS REGISTRATION: NCT03367182.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Yong Jae(이용재) ORCID logo https://orcid.org/0000-0003-0297-3116
Lee, Jung-Yun(이정윤) ORCID logo https://orcid.org/0000-0001-7948-1350
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.